Current Research in Translational Medicine最新文献

{"title":"Fatal acute graft-versus-host disease in Sézary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation","authors":"Gentiana Elena Trotta ,&nbsp;Giulia Ciangola ,&nbsp;Ilaria Cerroni ,&nbsp;Valeria Mezzanotte ,&nbsp;Andrea Nunzi ,&nbsp;Lucia Anemona ,&nbsp;Luca Savino ,&nbsp;Gottardo De Angelis ,&nbsp;Benedetta Mariotti ,&nbsp;Fabrizio Bonanni ,&nbsp;Elisa Meddi ,&nbsp;Annagiulia Zizzari ,&nbsp;Vito Mario Rapisarda ,&nbsp;Ilaria Mangione ,&nbsp;Antonio Bruno ,&nbsp;Maria Cantonetti ,&nbsp;Adriano Venditti ,&nbsp;Raffaella Cerretti","doi":"10.1016/j.retram.2024.103452","DOIUrl":"10.1016/j.retram.2024.103452","url":null,"abstract":"<div><p>Sézary syndrome (SS) is a rare and aggressive T-cell lymphoma with a poor prognosis in advanced stages. Allogeneic hematopoietic cell transplantation (allo-HCT) offers a potential cure, but complications such as graft-versus-host disease (GvHD) remain a clinical challenge. Mogamulizumab, a humanized anti-CC chemokine receptor 4 (CCR4) antibody, is sometimes used as a bridge to transplantation, but its potential interactions with allo-HCT are unclear. This report describes the case of a 37-year-old man with advanced SS who received mogamulizumab therapy followed by allo-HCT from an HLA-identical sibling donor. The patient developed severe gastrointestinal acute GvHD, which was treated with steroids and infliximab. However, the condition rapidly progressed to severe intestinal symptoms and life-threatening haemorrhagic shock, ultimately resulting in the patient's death. This case highlights a potential link between mogamulizumab and severe acute GvHD promoted by drug-induced suppression of regulatory T cells. Further research is required to fully understand the interaction between mogamulizumab and allo-HCT and to determine whether it is an optimal approach as a bridge to transplant therapy. This paradigmatic case suggests the need of personalizing transplant strategies by selecting appropriate conditioning therapy and GvHD prophylaxis to minimize potential toxicity.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 3","pages":"Article 103452"},"PeriodicalIF":4.1,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140785934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lactate level is an independent predictor of mortality in patients with hematologic malignancy receiving urgent chemotherapy in intensive care unit","authors":"Sukriye Miray Kilincer Bozgul ,&nbsp;Ilkce Akgun Kurtulmus ,&nbsp;Ajda Gunes ,&nbsp;Gorkem Koymen ,&nbsp;Devrim Bozkurt ,&nbsp;Zehra Tuba Karaman ,&nbsp;Karya Islamoglu ,&nbsp;Baris Ozkilic ,&nbsp;Burcu Barutcuoglu ,&nbsp;Fatma Feriha Cilli ,&nbsp;Nur Akad Soyer","doi":"10.1016/j.retram.2024.103451","DOIUrl":"https://doi.org/10.1016/j.retram.2024.103451","url":null,"abstract":"<div><h3>Background</h3><p>Intensive care unit (ICU) survival of cancer patients has improved. Urgent chemotherapy has become feasible in critically ill patients with specific organ dysfunction due to hematological malignancies.</p></div><div><h3>Objective</h3><p>The aim of the study was to assess ICU mortality rates and the factors associated with mortality in patients with hematologic malignancies receiving urgent chemotherapy in the ICU.</p></div><div><h3>Methods</h3><p>We retrospectively included all patients admitted to the ICU who received chemotherapy due to hematologic malignancy in 2012–2022.</p></div><div><h3>Results</h3><p>Of the 129 patients undergoing chemotherapy in the ICU, 50 (38.7 %) died during the ICU follow-up. The following conditions were significantly more common among nonsurvivors: presence of infection at the time of ICU admission (<em>p</em> &lt; 0.001), the requirement for mechanical ventilation during ICU stay (<em>p</em> &lt; 0.001), the need for noninvasive mechanical ventilation during ICU stay (<em>p</em> = 0.014), vasopressor support (<em>p</em> &lt; 0.001), and sepsis (<em>p</em> &lt; 0.001). Logistic regression analysis revealed that among laboratory parameters on ICU admission, lactate (<em>p</em> = 0.008), albumin (<em>p</em> = 0.022), C-reactive protein (<em>p</em> = 0.046), baseline sequential organ failure assessment (SOFA) score (<em>p</em> &lt; 0.001), newly developed heart failure (<em>p</em> = 0.006), and the requirement for vasopressor agents during ICU stay (<em>p</em> &lt; 0.001) significantly influenced the risk of mortality in the univariate analysis. The multivariate analysis revealed lactate levels (<em>p</em> = 0.047) on ICU admission as an independent predictor of mortality.</p></div><div><h3>Conclusion</h3><p>The development of heart failure and lactate levels on admission were the main predictors of mortality. Additionally, higher SOFA scores revealed that illness severity was closely associated with mortality. Future studies should focus on strategies to further reduce these risks and achieve the best outcomes for these patients.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 4","pages":"Article 103451"},"PeriodicalIF":4.1,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140645409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatological manifestations as a first sign of Erdheim-Chester Disease: A case report","authors":"Ahmad Ali Basha ,&nbsp;Mesk Al-Hammadi ,&nbsp;Zora Marjanovic ,&nbsp;Reyes Maria Martin-Rojas ,&nbsp;Tamim Alsuliman","doi":"10.1016/j.retram.2024.103450","DOIUrl":"https://doi.org/10.1016/j.retram.2024.103450","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 2","pages":"Article 103450"},"PeriodicalIF":4.1,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140644376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracorporeal membrane oxygenation (ECMO) during aplasia: A bridge towards myopericarditis recovery after autologous hematopoietic stem cell transplant for systemic sclerosis and recent Coronarovirus disease (COVID-19) vaccination","authors":"Carlotta Cacciatore ,&nbsp;Mathilde Baudet ,&nbsp;Estelle Jean ,&nbsp;Simona Presente ,&nbsp;Marylou Para ,&nbsp;Romain Sonneville ,&nbsp;Dimitri Arangalage ,&nbsp;Nassim Ait Abdallah ,&nbsp;Flore Sicre de Fontbrune ,&nbsp;Pedro Henrique Prata ,&nbsp;Benjamin Crichi ,&nbsp;Baptiste Hervier ,&nbsp;Nathalie Parquet ,&nbsp;Gilles Soulat ,&nbsp;Elie Mousseaux ,&nbsp;Richard K Burt ,&nbsp;Dominique Farge","doi":"10.1016/j.retram.2024.103449","DOIUrl":"https://doi.org/10.1016/j.retram.2024.103449","url":null,"abstract":"<div><p>Systemic sclerosis (SSc) is a rare autoimmune disease (AD), characterised by early diffuse vasculopathy, activation of the immune response and progressive skin and internal organ fibrosis. In severe progressive diffuse SSc (dSSc), autologous hematopoietic stem cell transplantation (aHSCT) improves survival, despite its own risk of complications and transplant related mortality (TRM).</p><p>We present herein the case of a dSSc patient undergoing aHSCT with low dose cyclophosphamide conditioning and sudden acute myopericarditis and cardiogenic shock, four weeks after a second mRNA SARS-CoV-2 vaccine (Pfizer) injection. Four days of extracorporeal membrane oxygenation (ECMO) support during the aplasia period, allowed to observe full cardiac function recovery and progressive SSc rehabilitation with sustained disease response at 30 months follow-up. This report illustrates, for the first time to our knowledge, that ECMO can be indicated despite aplasia during aHSCT and successfully used as a bridge towards heart function recovery in highly selected and fragile AD patients. We review the factors that may contribute to endothelial and myocardial stunning and acute reversible cardiac failure in SSc and aggravate intrinsic endothelial injury during the aHSCT procedure. These classically include: cyclophosphamide drug toxicity, viral infections and autoimmune activation with disease flair per se. In the COVID-19 pandemic times, acute myocarditis due to recent viral infection or mRNA vaccine per se, must also be considered.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 3","pages":"Article 103449"},"PeriodicalIF":4.1,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452318624000126/pdfft?md5=b5ba308a940814fa81061f5e19e1c50e&pid=1-s2.0-S2452318624000126-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140605626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of analytical methods for the production of expanded γδ T lymphocytes useful for therapeutic purposes","authors":"Fabio Morandi,&nbsp;Martina Della Lastra,&nbsp;Federico Zara,&nbsp;Irma Airoldi","doi":"10.1016/j.retram.2024.103445","DOIUrl":"10.1016/j.retram.2024.103445","url":null,"abstract":"<div><p>The use of γδ T lymphocytes as advanced therapeutic medicinal product has attracted much interest in the last years. Indeed, such cells are an ideal tool for the reconstitution of the immune system in patients receiving hematopoietic stem cell transplantation, due to their MHC-independent anti-tumor and anti-viral activities. We have here setup a protocol for the production of pure and functional γδ T lymphocytes, expanded from healthy donors’ mononuclear cells, and validated the analytical methods to identify them and to analyze their potency. Next, we performed stability studies to ensure that the cell product (γδ T cells) can be used after freezing and thawing. Notably, such protocol can be promptly translated to GMP-facility, since it has been designed using only clinical grade reagents.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 4","pages":"Article 103445"},"PeriodicalIF":4.1,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140087661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sofosbuvir (+) daclatasvir (+) ribavirin in Egyptian patients with hepatitis C virus: Therapeutic outcomes and the prognostic role of natural killer cells","authors":"Ahmed B. Zaid ,&nbsp;Shimaa K. Almady ,&nbsp;Samah M. Awad ,&nbsp;Mona G. Elabd ,&nbsp;Sara A. Saied ,&nbsp;AbdulRahman A Saied ,&nbsp;Alshimaa M Elmalawany","doi":"10.1016/j.retram.2024.103443","DOIUrl":"https://doi.org/10.1016/j.retram.2024.103443","url":null,"abstract":"<div><h3>Background</h3><p>One of the prominent causes of chronic liver disease worldwide is the hepatitis C virus (HCV). HCV believed that innate immunity contributes to a sustained virological response (SVR) to the treatment of Sofosbuvir (SOF) (+) Daclatasvir (DCV) (+) Ribavirin (RBV). This study aimed to evaluate the impact of SOF (+) DCV (+) RBV therapy and persistent HCV infection on the subset of natural killer cells (NK) in HCV genotype four patients from Egypt.</p></div><div><h3>Materials and Methods</h3><p>One hundred and ten patients with persistent HCV infections requiring SOF (+) DCV (+) RBV therapy were grouped, and a flow cytometry (FCM) study of the NK cell subset in peripheral blood was performed. The assessment was performed before and after three and/or six months of the cessation of viral suppression therapy when a patient had a long-term viral response (SVR). One hundred and ten volunteers from the National Liver Institute^’s (NLI) blood bank were selected as controls.</p></div><div><h3>Results</h3><p>Patients with chronic HCV infection before therapy had considerably lower CD16⁺ and CD3⁻ CD56⁺ cells than controls. Their levels increase during SOF (+) DCV (+) RBV therapy. In patients with SVR during treatment, CD16⁺ and CD3^– CD56⁺ cells increased significantly compared to those who did not get SVR. Furthermore, CD56⁺ cells were significantly higher in patients with persistent infection before treatment than controls but diminished with the response to treatment.</p></div><div><h3>Conclusion</h3><p>: NK cell activation following SOF (+) DCV (+) RBV therapy and polarization to cytotoxicity occurred early in HCV antiviral therapy and was elevated in the respondents. Our data illustrated that establishing an inhibitory cytotoxic NK profile is related to therapeutic outcomes.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 3","pages":"Article 103443"},"PeriodicalIF":4.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140042812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide","authors":"Emine Begum Gencer ,&nbsp;Hasan Yalim Akin ,&nbsp;Selami Kocak Toprak ,&nbsp;Eylul Turasan ,&nbsp;Mahsa Yousefzadeh ,&nbsp;Pinar Yurdakul-Mesutoglu ,&nbsp;Murat Cagan ,&nbsp;Mehmet Murat Seval ,&nbsp;Doruk Cevdi Katlan ,&nbsp;Klara Dalva ,&nbsp;Mehmet Sinan Beksac ,&nbsp;Meral Beksac","doi":"10.1016/j.retram.2024.103444","DOIUrl":"https://doi.org/10.1016/j.retram.2024.103444","url":null,"abstract":"<div><h3>Background</h3><p>High self-renewal capacity and most permissive nature of umbilical cord blood (CB) results with successful transplant outcomes but low hematopoietic stem and progenitor cell (HSPC) counts limits wider use. In order to overcome this problem <em>ex vivo</em> expansion with small molecules such as Valproic acid (VPA) or Nicotinamide (NAM) have been shown to be effective. To the best of our knowledge, the combinatory effects of VPA and NAM on HSPC expansion has not been studied earlier. The aim of this study was to analyze <em>ex vivo</em> and <em>in vivo</em> efficacy of VPA and NAM either alone or in combination in terms of expansion and engraftment.</p></div><div><h3>Methods</h3><p>A total of 44 CB units were included in this study. To determine the <em>ex vivo</em> and <em>in vivo</em> efficacy, human CB CD34+ cells were expanded with VPA and/or NAM and colony forming unit (CFU) assay was performed on expanded HSPC. Xenotransplantation was performed simultaneously by intravenous injection of expanded HSPC to <em>NOD-SCID</em> gamma (NSG) mice (<em>n</em> = 22). Significance of the difference between the expansion groups or xenotransplantation models was analyzed using <em>t</em>-test, Mann-Whitney, ANOVA or Kruskal-Wallis tests as appropriate considering the normality of distributions and the number of groups analyzed.</p></div><div><h3>Results</h3><p><em>In vitro</em> CD34+ HSPC expansion fold relative to cytokines-only was significantly higher with VPA compared to NAM [2.23 (1.07–5.59) <em>vs</em> 1.48 (1.00–4.40); <em>p</em> &lt; 0.05]. Synergistic effect of VPA+NAM has achieved a maximum relative expansion fold at 21 days (D21) of incubation [2.95 (1.00–11.94)]. There was no significant difference between VPA and VPA+NAM D21 (<em>p</em> = 0.44). Fold number of colony-forming unit granulocyte-macrophage (CFU-GM) colonies relative to the cytokine-only group was in favor of NAM compared to VPA [1.87 (1.00–3.59) <em>vs</em> 1.00 (1.00–1.81); <em>p</em> &lt; 0.01]. VPA+NAM D21 [1.62 (1.00–2.77)] was also superior against VPA (<em>p</em> &lt; 0.05). There was no significant difference between NAM and VPA+NAM D21. Following human CB34+ CB transplantation (CBT) in the mouse model, fastest <em>in vivo</em> leukocyte recovery was observed with VPA+NAM expanded cells (6 ± 2 days) and the highest levels of human CD45 chimerism was detectable with VPA-expanded CBT (VPA: 5.42 % at day 28; NAM: 2.45 % at day 31; VPA+NAM 1.8 % at day 31).</p></div><div><h3>Conclusion</h3><p>Our study results suggest using VPA alone, rather than in combination with NAM or NAM alone, to achieve better and faster expansion and engraftment of CB HSPC.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 3","pages":"Article 103444"},"PeriodicalIF":4.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140042813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of next-generation sequencing in acquired amegakaryocytic thrombocytopenic purpura","authors":"Lorenzo Lazzari ,&nbsp;Lucia Bongiovanni ,&nbsp;Paola Ronchi ,&nbsp;Gregorio Maria Bergonzi ,&nbsp;Camilla Gariazzo ,&nbsp;Elisa Diral ,&nbsp;Fabio Ciceri ,&nbsp;Andrea D'Alessio ,&nbsp;Maurilio Ponzoni","doi":"10.1016/j.retram.2024.103441","DOIUrl":"10.1016/j.retram.2024.103441","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 1","pages":"Article 103441"},"PeriodicalIF":4.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139590521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of chimeric antigen receptor therapy beyond oncology: A bibliometric and visualized analysis","authors":"Linxin Yang ,&nbsp;Jinshen He ,&nbsp;Jiahao Liu ,&nbsp;Tianjian Xie ,&nbsp;Qi Tang","doi":"10.1016/j.retram.2024.103442","DOIUrl":"10.1016/j.retram.2024.103442","url":null,"abstract":"<div><h3>Purpose</h3><p>Chimeric antigen receptor therapy beyond oncology has gained increasing attention. While a substantial number of publications have emerged in recent years, there has been a paucity of conducted bibliometric studies. Our objective is to systematically summarize and visually analyze the literature in the field of chimeric antigen receptors therapy beyond oncology and explore hotspots in this field.</p></div><div><h3>Methods</h3><p>Web of Science Core Collection was selected as the data source, and the data was retrieved on December 23, 2022, according to the search strategy. CiteSpace 6.1.R6 and Vosviewer 1.6.18 were used to analyze publications and explore research hotspots and directions.</p></div><div><h3>Results</h3><p>A total of 338 publications written by 1832 authors from 516 institutions in 42 countries/regions were selected for the analysis. The number of publications is steadily increasing annually. The United States emerged as the primary contributor, and University of Pennsylvania was the leading institution. Frontiers in Immunology boasted the highest number of published papers. Kitchen SG, Riley JL, and Scott DW were the most productive researchers in this field. The keyword cluster analysis identified HIV, autoimmune diseases, transplant related diseases and COVID-19 as the primary focus areas within the realm of chimeric antigen receptor therapy beyond oncology.</p></div><div><h3>Conclusion</h3><p>The advancement of chimeric antigen receptor therapy beyond oncology has witnessed rapid progress in recent years. We have explored the hotspots and research directions in this field. It is hoped that this study could provide references and directions for future clinical researches.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 3","pages":"Article 103442"},"PeriodicalIF":4.1,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139769994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical applications of immunosequencing","authors":"B. Bardwell ,&nbsp;J. Bay ,&nbsp;Z. Colburn","doi":"10.1016/j.retram.2024.103439","DOIUrl":"10.1016/j.retram.2024.103439","url":null,"abstract":"<div><p>Technological advances in high-throughput sequencing have opened the door for the interrogation of adaptive immune responses at unprecedented scale. It is now possible to determine the sequences of antibodies or T-cell receptors produced by individual B and T cells in a sample. This capability, termed immunosequencing, has transformed the study of both infectious and non-infectious diseases by allowing the tracking of dynamic changes in B and T cell clonal populations over time. This has improved our understanding of the pathology of cancers, autoimmune diseases, and infectious diseases. However, to date there has been only limited clinical adoption of the technology. Advances over the last decade and on the horizon that reduce costs and improve interpretability could enable widespread clinical use. Many clinical applications have been proposed and, while most are still undergoing research and development, some methods relying on immunosequencing data have been implemented, the most widespread of which is the detection of measurable residual disease. Here, we review the diagnostic, prognostic, and therapeutic applications of immunosequencing for both infectious and non-infectious diseases.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 3","pages":"Article 103439"},"PeriodicalIF":4.1,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139461405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}